Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors

Pigment Cell and Melanoma Research

Volumn 25, Issue 5, 2012, Pages 569-572

  Anforth, Rachael ^a,b   Tembe, Varsha ^c   Blumetti, Tatiana ^a,b   Fernandez Peñas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

BRAF inhibitors; Melanoma; Squamous cell carcinoma; Verrucal keratosis

Indexed keywords

DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; VEMURAFENIB;

ARTICLE; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; KERATINOCYTE; KERATOACANTHOMA; KERATOSIS; METASTATIC MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; OVERALL SURVIVAL; PAPULE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECEPTOR GENE; SKIN CARCINOMA; VERRUCAL KERATOSIS;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; EXONS; HUMANS; KERATOSIS; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; WARTS;

EID: 84865566354     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.01031.x     Document Type: Article

References (10)

1. Anforth, R., Blumetti, T., Kefford, R., Sharma, R., Scolyer, R., Kossard, S., Long, G.V. and Fernandez-Penas, P. (2012). Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of BRAF Mutaant Metastatic Melanoma. Br. J. Dermatol. In Press.
2. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
3. Lacouture, M.E., Chapman, P.B., Ribas, A. et al. (2011). Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J. Clin. Oncol. (Meeting Abstracts) 29, Abstract 8520.
4. Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
5. Oberholzer, P.A., Kee, D., Dziunycz, P. et al. (2011). RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321.
6. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
7. Ribas, A., and Flaherty, K.T. (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426-433.
8. Robert, C., Arnault, J.P., and Mateus, C. (2011). RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr. Opin. Oncol. 23, 177-182.
9. Samuels, Y., Wang, Z., Bardelli, A. et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554.
10. Su, F., Viros, A., Milagre, C. et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.